Containment Gene Editing Immune Response In-Vivo 
Drug Discovery World
DECEMBER 15, 2022
As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Early phase clinical trials for gene editing therapies.
Pharma Marketing Network
JANUARY 20, 2021
It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.
Expert insights. Personalized for you.
52 
Let's personalize your content